NFKF is a synthetic fragment derived from rat hemo... - BV FAPESP
Busca avançada
Ano de início
Entree
Conteúdo relacionado
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

NFKF is a synthetic fragment derived from rat hemopressin that protects mice from neurodegeneration

Texto completo
Autor(es):
Heimann, Andrea S. [1] ; Giardini, A. C. [2] ; Sant'Anna, M. B. [2] ; Dos Santos, Nilton B. [3] ; Gewehr, Mayara C. F. [3] ; Munhoz, Carolina D. [3] ; Castro, Leandro M. [4] ; Picolo, Gisele [2] ; Remer, Ricardo A. [5] ; Ferro, Emer S. [3]
Número total de Autores: 10
Afiliação do(s) autor(es):
[1] Proteimax Biotechnol, BR-05581001 Sao Paulo - Brazil
[2] Butantan Inst, Special Lab Pain & Signaling, BR-05503900 Sao Paulo - Brazil
[3] Univ Sao Paulo, Biomed Sci Inst, Dept Pharmacol, BR-05508900 Sao Paulo - Brazil
[4] Sao Paulo State Univ, Biosci Inst, BR-11330900 Sao Vicente - Brazil
[5] Remer Consultores Ltda, BR-01411001 Sao Paulo, SP - Brazil
Número total de Afiliações: 5
Tipo de documento: Artigo Científico
Fonte: Neuroscience Letters; v. 721, MAR 16 2020.
Citações Web of Science: 0
Resumo

Previous studies suggested the pharmacological potential of rat hemopressin (PVNFKFLSH) and its shorter synthetic peptide NFKF, to protect from pilocarpine-induced seizures in mice. Orally administered NFKF was shown to be hundred times more potent than cannabidiol in delaying the first seizure induced by pilocarpine in mice. Here, using an experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis we have shown that C57BL/6 J mice orally administrated with NFKF (500 mu g/kg) presented better EAE clinical scores and improved locomotor activity compared to saline administrated control mice. NFKF blocked the production of IL-1beta and IL-6, and has high scores binding cannabinoid type 2 receptors. Therefore, NFKF is an exciting new possibility to neurodegenerative diseases therapeutics. (AU)

Processo FAPESP: 16/04000-3 - Farmacologia de oligopeptidases e peptídeos intracelulares
Beneficiário:Emer Suavinho Ferro
Modalidade de apoio: Auxílio à Pesquisa - Temático